Synthetic patient data can lower barriers to building clinical AI in Africa, but only when paired with real local data and robust governance; without hybrid training, domain adaptation, and stronger validation infrastructure, fidelity gaps risk biased care and wasted investment.
On the use of synthetic data for healthcare AI in Africa: Technical performance, governance challenges, and policy readiness
Synthetic data can materially support healthcare AI development in Africa—especially in hybrid synthetic–real pipelines and with domain adaptation—but fidelity gaps, infrastructure shortfalls, and weak governance limit clinical and economic benefits and risk introducing bias.
Purpose Synthetic data has emerged as a promising solution to overcome the shortage of clinical datasets needed for training healthcare artificial intelligence (AI) models. This study examined how synthetic data can support AI development in Africa's healthcare by analyzing its technical performance, fidelity limitations, and governance implications within low-resource health systems. Methods A Critical Literature Review was conducted on scholarly and technical literature focused on the use of synthetic data for AI in healthcare across African settings. Databases searched included Scopus, Web of Science, PubMed, and Google Scholar. Thematic analysis identified trends in synthetic data generation, fidelity, domain adaptation, and adoption challenges in African healthcare AI. Results Drawing on interdisciplinary evidence, the analysis demonstrates how addressing technical challenges, improving synthetic data fidelity, leveraging domain adaptation techniques, and confronting practical adoption barriers are critical to enhancing the reliability and applicability of synthetic data for AI-driven healthcare in Africa. Four themes emerged from the analysis. First, hybrid synthetic–real datasets consistently outperform synthetic-only models. Second, fidelity gaps introduced bias risk and misclassification. Third, domain adaptation remains underused in low-resource contexts. Fourth, infrastructure gaps, weak regulation, and clinician skepticism hindered the adoption of synthetic data. Conclusion Synthetic data can enhance AI-enabled healthcare in Africa if it is embedded within regulatory frameworks, validated through hybrid modeling, and supported by investment in infrastructure and capacity-building. This study highlights the intersection of synthetic data, healthcare AI, data fidelity, domain adaptation, and governance considerations in African health systems, underscoring the need for robust health technology assessment processes.
Summary
Main Finding
Synthetic data can meaningfully support development of healthcare AI in Africa, but its value depends on technical choices (notably hybrid synthetic–real approaches), improvements in fidelity and domain adaptation, and stronger governance and infrastructure. Without those, synthetic data risks introducing bias and limiting clinical and economic benefits.
Key Points
- Hybrid datasets (synthetic data combined with real patient data) consistently yield better model performance than synthetic-only training across reviewed studies.
- Fidelity gaps in synthetic data (missing rare events, distributional shifts, artefacts) create risks of misclassification and biased outcomes when models are deployed in real-world African clinical settings.
- Domain adaptation techniques (transfer learning, fine-tuning on local data) are underutilized in low-resource contexts despite their potential to improve generalization to local populations and care processes.
- Practical adoption challenges are substantial: limited digital infrastructure, sparse local computing capacity, weak regulatory frameworks for synthetic data use, and clinician skepticism about model validity.
- Interdisciplinary evidence suggests technical fixes alone are insufficient: governance, validation pipelines (e.g., health technology assessment), and capacity building are needed for safe, effective uptake.
Data & Methods
- Approach: Critical literature review and thematic analysis synthesizing scholarly and technical literature on synthetic data for healthcare AI in African settings.
- Sources searched: Scopus, Web of Science, PubMed, Google Scholar (peer-reviewed articles, technical reports, and policy analyses).
- Themes coded: synthetic data generation methods, fidelity and bias, domain adaptation/transfer learning, adoption and governance barriers.
- Evidence base: interdisciplinary — machine learning evaluations, clinical validation studies, implementation and governance analyses.
- Limitations: potential publication bias toward positive technical results, heterogeneity in study settings and outcome metrics, limited empirical deployment studies from many African countries, and sparse economic evaluations in the reviewed literature.
Implications for AI Economics
- Cost–benefit trade-offs:
- Synthetic data can reduce costs and logistical barriers of collecting large clinical datasets (lowering data acquisition and privacy-compliance expenses), but high-fidelity synthetic generation and validation require upfront investment in modelling expertise and compute.
- Hybrid approaches may deliver the best economic return by reducing need for large-scale primary data collection while maintaining acceptable performance; however they require modest real-data collection costs for fine-tuning and validation.
- Investment priorities:
- Financing should target computational infrastructure, local model validation capacity, and training for clinicians and data scientists to increase adoption and trust.
- Funding for domain adaptation research and tools that make fine-tuning models with small local datasets cheaper will raise marginal benefits of synthetic data.
- Market and regulatory effects:
- Clear regulatory standards for synthetic data quality, provenance, and acceptable validation pipelines will lower transaction costs, reduce liability risk, and stimulate private-sector offerings (synthetic-data services, marketplaces).
- Weak or absent regulation increases uncertainty and may deter investment or lead to adoption of low-quality synthetic products with negative economic and clinical externalities.
- Equity and distributional risks:
- Fidelity-related biases risk concentrating harms among underrepresented populations, potentially increasing healthcare costs and welfare losses. Economic evaluation and auditing for distributional impacts should be integrated into procurement and reimbursement decisions.
- Health technology assessment (HTA) and procurement:
- HTA frameworks should be adapted to evaluate models trained on synthetic or hybrid data, incorporating metrics for fidelity, domain generalization, and economic impact (cost-effectiveness, budget impact, distributional effects).
- Procurement contracts can require staged validation (pilot, local fine-tuning) and performance-linked payments to align incentives and reduce adoption risk.
- Policy recommendations (summary):
- Prioritize hybrid-data approaches in pilots and procurement.
- Invest in local infrastructure and human capital to validate and adapt models.
- Develop regulatory guidance and minimum fidelity standards for synthetic healthcare data.
- Incorporate distributional impact and uncertainty into economic evaluations and HTA for AI systems.
Assessment
Paper Typereview_meta
Evidence Strengthmedium — The paper synthesizes interdisciplinary empirical evaluations (ML benchmarks, clinical validation studies) and policy analyses showing consistent patterns (e.g., hybrid datasets outperform synthetic-only training), but it is not a primary causal study: evidence is heterogeneous, often lab-based, limited in real-world African deployments, and subject to publication bias and inconsistent outcome measures.
Methods Rigormedium — Searches covered major databases and grey literature and the authors conducted structured thematic coding, which supports breadth and coherence; however, the review appears qualitative rather than a pre-registered systematic review or meta-analysis, with heterogeneous study designs and no formal quantitative synthesis or risk-of-bias assessment.
SampleA heterogeneous corpus of peer-reviewed articles, technical reports, and policy analyses identified via Scopus, Web of Science, PubMed and Google Scholar, comprising machine-learning model evaluations (synthetic vs real or hybrid training), a limited number of clinical validation studies in African settings, implementation case studies, and governance/policy papers; many countries and clinical domains are sparsely represented and economic evaluations are rare.
Themesadoption governance
GeneralizabilityLimited empirical deployments in many African countries — results may reflect a subset of settings with better data or capacity, Substantial heterogeneity in clinical domains, model types, and synthetic-data generation methods limits comparability, Findings driven mainly by technical evaluations (benchmarks) may not generalize to real-world clinical workflows or scale-up, Infrastructure and regulatory contexts vary widely across Africa, constraining transferability of governance and procurement recommendations, Conclusions specific to healthcare and may not apply to other sectors or high-income settings
Claims (14)
| Claim | Direction | Confidence | Outcome | Details |
|---|---|---|---|---|
| Hybrid datasets (synthetic data combined with real patient data) consistently yield better model performance than synthetic-only training across reviewed studies. Output Quality | positive | medium | model performance metrics (e.g., predictive accuracy, AUROC, sensitivity/specificity) when trained on hybrid vs. synthetic-only datasets |
0.14
|
| Fidelity gaps in synthetic data (missing rare events, distributional shifts, artefacts) create risks of misclassification and biased outcomes when models are deployed in real-world African clinical settings. Output Quality | negative | high | misclassification rates, biased prediction errors, distributional shifts between synthetic and real clinical data |
0.24
|
| Domain adaptation techniques (transfer learning, fine-tuning on local data) are underutilized in low-resource African contexts despite their potential to improve generalization to local populations and care processes. Output Quality | null_result | medium | use of domain adaptation methods and resulting generalization/performance improvement on local validation sets |
0.14
|
| Without improvements in fidelity and domain adaptation, synthetic data risks introducing bias and limiting clinical and economic benefits. Output Quality | negative | medium | distributional bias, clinical utility (e.g., diagnostic accuracy, decision impact), and economic outcomes (cost-effectiveness, welfare impact) |
0.14
|
| Practical adoption challenges in African settings are substantial: limited digital infrastructure, sparse local computing capacity, weak regulatory frameworks for synthetic data use, and clinician skepticism about model validity. Adoption Rate | negative | high | infrastructure availability (digital records, compute), regulatory maturity indicators, clinician acceptance/uptake measures |
0.24
|
| Technical fixes alone are insufficient: governance, validation pipelines (e.g., health technology assessment), and capacity building are needed for safe, effective uptake of synthetic-data–trained AI. Governance And Regulation | neutral | medium | safe/effective uptake operationalized via validated deployment, regulatory compliance, and sustained clinical adoption |
0.14
|
| Synthetic data can reduce costs and logistical barriers of collecting large clinical datasets, lowering data-acquisition and privacy-compliance expenses, but high-fidelity synthetic generation and validation require upfront investment in modelling expertise and compute. Firm Productivity | mixed | medium | data-acquisition costs, privacy/compliance costs, upfront modelling and compute expenditures, net cost savings or increases |
0.14
|
| Hybrid approaches may deliver the best economic return by reducing need for large-scale primary data collection while maintaining acceptable performance, but they require modest real-data collection costs for fine-tuning and validation. Firm Productivity | positive | medium | cost-effectiveness (economic return), model performance after fine-tuning on modest local datasets |
0.14
|
| Clear regulatory standards for synthetic data quality, provenance, and acceptable validation pipelines will lower transaction costs, reduce liability risk, and stimulate private-sector offerings (synthetic-data services, marketplaces). Governance And Regulation | positive | low | transaction costs, regulatory compliance uncertainty, market entry of synthetic-data service providers |
0.07
|
| Weak or absent regulation increases uncertainty and may deter investment or lead to adoption of low-quality synthetic products with negative economic and clinical externalities. Governance And Regulation | negative | medium | investment levels, prevalence of low-quality products, clinical/economic externalities (harm incidence, wasted expenditures) |
0.14
|
| Fidelity-related biases risk concentrating harms among underrepresented populations, potentially increasing healthcare costs and welfare losses; economic evaluation and auditing for distributional impacts should be integrated into procurement and reimbursement decisions. Inequality | negative | medium | differential error rates across subpopulations, distributional welfare impacts, incremental healthcare costs attributable to biased model outputs |
0.14
|
| Health technology assessment (HTA) frameworks should be adapted to evaluate models trained on synthetic or hybrid data, incorporating metrics for fidelity, domain generalization, and economic impact (cost-effectiveness, budget impact, distributional effects). Governance And Regulation | neutral | medium | HTA evaluation metrics (fidelity scores, generalization performance, cost-effectiveness estimates, distributional impact assessments) |
0.14
|
| Procurement contracts for AI systems can require staged validation (pilot, local fine-tuning) and performance-linked payments to align incentives and reduce adoption risk. Governance And Regulation | positive | low | procurement structures, incidence of staged validation, alignment of vendor performance with payments, reduced adoption risk |
0.07
|
| Priority investments should target computational infrastructure, local model validation capacity, and training for clinicians and data scientists to increase adoption and trust in synthetic-data–supported AI. Skill Acquisition | positive | high | availability of compute infrastructure, numbers/quality of local validation projects, clinician and data-scientist training metrics, adoption/trust indicators |
0.24
|
Entities
Synthetic data (method)
Hybrid synthetic–real datasets (method)
Domain adaptation (method)
Real patient data (dataset)
African clinical populations (population)
Model performance (outcome)
Data fidelity (fidelity gaps) (outcome)
Bias / distributional harms (outcome)
Transfer learning (method)
Fine-tuning (method)
Health technology assessment (HTA) (method)
African clinical settings (population)
Underrepresented populations (population)
Misclassification errors (outcome)
Cost–benefit trade-offs (outcome)
Cost-effectiveness (outcome)
Critical literature review (method)
Thematic analysis (method)
Machine learning evaluation (method)
Clinical validation (method)
Clinicians (healthcare providers) (population)
Distributional impacts (equity effects) (outcome)
Scopus (institution)
Web of Science (institution)
PubMed (dataset)
Google Scholar (dataset)